Zeleciment basivarsen not checked

Dyne Therapeutics · DYNE-101

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
2 active
2 in total · 2 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
Tested for
Myotonic Dystrophy Type 1 (DM1) (2 trials), DM1, Myotonic Dystrophy, Steinert Disease, Steinert
Main trialPhase 3
“The purpose of the study is to assess the efficacy, safety, and tolerability of zeleciment basivarsen (DYNE-101) for the treatment of myotonic dystrophy 1 (DM1).”In the company’s words, NCT07486934 on ClinicalTrials.gov
Other names
DYNE-101

Other drugs for Myotonic Dystrophy Type 1 (DM1)

All 11 drugs for Myotonic Dystrophy Type 1 (DM1)

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 3Recruiting Jul 2028 Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1
Phase 1/2Active, not recruiting Jul 2029 Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Zeleciment basivarsen

Following is part of Solo: you see every change to Zeleciment basivarsen the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in